ميد شرب سير

A composition in dosage unit form useful for inducing regression and/or palliation of cancer diseases in mammals comprising from about one mg. to about 200 mg. per kilogram of body weight per daily dosage unit of a compound selected from the group consisting of 1,4-bis[(2-aminoethy1)amino]-5,8-dihydroxyanthraquinone, 1,4-bis[2-(methylamino)ethylamino]-5,8-dihydroxyanthraquinone, 1,4-bis[2-(1,3-oxazolidin-l-yl)ethylamino]-5,8rdihydroxyanthraquinone, 1,4-bis[2--(tetrahydro-1,3-oxazin/-1-yl)ethylamino]-5,8-dihydroxyanthraquinone, 1,4-bis[2-(1,3-0xazolidin-2-one-1-y1)ethylamino]-5,8--dihydroxyanthraquinone, 1,4-bis[2-(tetrahydro-1,3-oxazin-2--one-1-y1)ethylamino]-5,8-dihydroxyanthraquinone, the leuco bases thereof, the tautomers thereof and the pharmacologically acceptable acid-addition salks thereof; in association with a pharmaceutical carrier.

REMARKS

The preceding amendments are proper at this time in order to present the claims in a more consistent form for examination.

The Examiner's attention is hereby drawn to the fact of the issuance of the parent application, Serial No. 923,602 as U.S. Patent No. 4,197,249

spectfully submitted,

Attorney for Applicants Registration No. 19,087

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Wa

Deposit)

WARD A. ONROY Mahe of Applicant, Assignee ONROY.

Registered Representative

Date of Signature